TALL-104 (ATCC® CRL-11386)

Organism: Homo sapiens, human  /  Cell Type: T lymphoblast  /  Tissue: Peripheral blood  /  Disease: acute lymphoblastic leukemia

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue
Peripheral blood
Cell Type T lymphoblast
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Disease acute lymphoblastic leukemia
Age 2 years
Gender male
Storage Conditions liquid nitrogen vapor phase
Karyotype 46, XY; t(11;14)(p13;q11)
Derivation
The TALL-104 line was established from the peripheral blood of a child in relapse with T-ALL.
Clinical Data
male
peripheral blood of a child in relapse with T-ALL
Antigen Expression
CD2 +; CD3 +; CD7 +; CD8 +; CD56 +; CD4 -; CD16 -
Receptor Expression
T cell antigen receptor alpha/beta (TCR), expressed
interleukin 2 (IL-2), expressed
interleukin 2 (IL-2); T cell antigen receptor alpha/beta (TCR)
Genes Expressed
interferon gamma (IFN gamma); tumor necrosis factor alpha (TNF alpha); granulocyte monocyte colony stimulating factor (GM-CSF)
Cellular Products
interferon gamma (IFN gamma); tumor necrosis factor alpha (TNF alpha); granulocyte monocyte colony stimulating factor (GM-CSF)
Comments
The TALL-104 line was established from the peripheral blood of a child in relapse with T-ALL.
The cells are highly cytotoxic and are capable of tumor destruction in vivo and in vitro.
IL-2 is required from optimal growth and long term cultivation, but the cells can be grown for short periods without IL-2 (growth will be slower).
The cells are positive for the alpha/beta TCR and negative for gamma/delta TCR.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. ATCC 30-2005. To make the complete growth medium, add the following components to the base medium: 50 to 100 units/ml recombinant human IL-2; 2.5 microgram/ml human albumin; 0.5 microgram/ml D-mannitol; fetal bovine serum to a final concentration of 20%.
Subculturing
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at least 8 X 105 cells/mL.
Note: IL-2 rapidly loses its potency in medium, it is important that fresh IL-2 be used.
Interval: Maintain between 4 X 105 and 1 X 10cells/mL.
Medium Renewal: Add medium as cell density increases
Cryopreservation
Freeze medium: Complete growth medium supplemented with 50% fetal bovine serum, and 10% DMSO. Freeze at a cell density of at least 15 X 10(6) cells/ml
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Growth Conditions: Successful growth of this cell line is very dependent upon the quality of IL-2 used in the growth medium. ATCC recommends using the highest quality IL-2 available.
STR Profile
Amelogenin: X,Y
CSF1PO: 10,11
D13S317: 9,12
D16S539: 12
D5S818: 12,13
D7S820: 7,13
THO1: 7,9
TPOX: 8,9
vWA: 14,18
Name of Depositor Wistar Institute
References

Santoli D, et al. Cytotoxic T-ALL cell lines and uses therefor. US Patent 5,272,082 dated Dec 21 1993

O'Connor R, et al. Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood 77: 1534-1545, 1991. PubMed: 1706955

Cesano A, et al. Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. Blood 77: 2463-2474, 1991. PubMed: 2039829

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Santoli D, et al. Cytotoxic T-ALL cell lines and uses therefor. US Patent 5,272,082 dated Dec 21 1993

O'Connor R, et al. Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood 77: 1534-1545, 1991. PubMed: 1706955

Cesano A, et al. Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. Blood 77: 2463-2474, 1991. PubMed: 2039829